While GP96 expression does not impact OS or DFS, high GP96 expression is associated with higher rates of locoregional recurrence, suggesting its potential as an additional biomarker for locoregional invasiveness in BC treatment planning and follow-up. This evidence concerns the gene HSP90B1 and breast cancer.